These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 32162417)

  • 1. Retrospective analysis of the effectiveness and tolerability of nab-paclitaxel in Chinese elderly patients with advanced non-small-cell lung carcinoma.
    Wang S; Liang Q; Chi Y; Zhuo M; An T; Duan J; Wang Z; Wang Y; Zhong J; Yang X; Chen H; Wang J; Zhao J
    Thorac Cancer; 2020 May; 11(5):1149-1159. PubMed ID: 32162417
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nab-paclitaxel in older patients with non-small cell lung cancer who have developed disease progression after platinum-based doublet chemotherapy.
    Weiss JM; Pennell N; Deal AM; Morgensztern D; Bradford DS; Crane J; West HJ; Lee C; Pecot C; Stevenson JP; Irvin W; Socinski M; Stinchcombe T; Villaruz LC; Muss HB
    Cancer; 2020 Mar; 126(5):1060-1067. PubMed ID: 31943168
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nanoparticle albumin-bound paclitaxel in elder patients with advanced squamous non-small-cell lung cancer: A retrospective study.
    Liu Y; Dong Y; Zhu H; Jing W; Guo H; Yu J
    Cancer Med; 2020 Feb; 9(4):1365-1373. PubMed ID: 31876976
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A single-arm phase II trial of weekly nanoparticle albumin-bound paclitaxel (nab-paclitaxel) monotherapy after standard of chemotherapy for previously treated advanced non-small cell lung cancer.
    Kato Y; Okuma Y; Watanabe K; Yomota M; Kawai S; Hosomi Y; Okamura T
    Cancer Chemother Pharmacol; 2019 Aug; 84(2):351-358. PubMed ID: 30993397
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of weekly nab®-paclitaxel in combination with carboplatin as first-line therapy in elderly patients with advanced non-small-cell lung cancer.
    Socinski MA; Langer CJ; Okamoto I; Hon JK; Hirsh V; Dakhil SR; Page RD; Orsini J; Zhang H; Renschler MF
    Ann Oncol; 2013 Feb; 24(2):314-321. PubMed ID: 23123509
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nanoparticle Albumin-bound Paclitaxel Plus Carboplatin Induction Followed by Nanoparticle Albumin-bound Paclitaxel Maintenance in Squamous Non-Small-cell Lung Cancer (ABOUND.sqm): A Phase III Randomized Clinical Trial.
    Spigel DR; Jotte RM; Aix SP; Gressot L; Morgensztern D; McCleod M; Socinski MA; Daniel D; Juan-Vidal O; Mileham KF; West H; Page R; Reinmuth N; Knoble J; Chen T; Bhore R; Wolfsteiner M; Ong TJ; Gridelli C; Thomas M;
    Clin Lung Cancer; 2021 Jan; 22(1):6-15.e4. PubMed ID: 33097414
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I study of weekly nab-paclitaxel plus carboplatin and concurrent thoracic radiotherapy in elderly patients with unresectable locally advanced non-small cell lung cancer.
    Omori S; Harada H; Mori K; Hisamatsu Y; Tsuboguchi Y; Yoshioka H; Morinaga R; Daga H; Kurata T; Takahashi T
    Invest New Drugs; 2022 Feb; 40(1):106-114. PubMed ID: 34495421
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and Safety of Nab-Paclitaxel as Second-line Chemotherapy for Locally Advanced and Metastatic Non-small Cell Lung Cancer.
    Gong W; Sun P; Mu Z; Liu J; Yu C; Liu A
    Anticancer Res; 2017 Aug; 37(8):4687-4691. PubMed ID: 28739772
    [TBL] [Abstract][Full Text] [Related]  

  • 9. First-line nab-paclitaxel plus carboplatin for patients with advanced non-small cell lung cancer: Results of the NEPTUN study.
    Dechow T; Riera-Knorrenschild J; Hackanson B; Janssen J; Schulz H; Chiabudini M; Fischer von Weikersthal L; Budweiser S; Nacke A; Taeuscher D; Welslau M; Potthoff K
    Cancer Med; 2021 Nov; 10(22):8127-8137. PubMed ID: 34668662
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase II study of nanoparticle albumin-bound paclitaxel plus carboplatin as the first-line therapy in elderly patients with previously untreated advanced non-small cell lung cancer.
    Okuma Y; Hosomi Y; Takahashi S; Nakahara Y; Watanabe K; Nagamata M; Takagi Y; Mikura S
    Cancer Chemother Pharmacol; 2016 Aug; 78(2):383-8. PubMed ID: 27339149
    [TBL] [Abstract][Full Text] [Related]  

  • 11. nab-Paclitaxel/carboplatin in elderly patients with advanced squamous non-small cell lung cancer: a retrospective analysis of a Phase III trial.
    Gridelli C; Chen T; Ko A; O'Brien ME; Ong TJ; Socinski MA; Postmus PE
    Drug Des Devel Ther; 2018; 12():1445-1451. PubMed ID: 29872267
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II Study of Modified Carboplatin Plus Weekly Nab-Paclitaxel in Elderly Patients with Non-Small Cell Lung Cancer: North Japan Lung Cancer Study Group Trial 1301.
    Miyauchi E; Inoue A; Usui K; Sugawara S; Maemondo M; Saito H; Fujita Y; Kato T; Suzuki T; Harada T; Watanabe H; Nakagawa T; Ichinose M
    Oncologist; 2017 Jun; 22(6):640-e59. PubMed ID: 28526722
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Phase I/II Study of Biweekly Carboplatin and Nab-paclitaxel With Concurrent Radiotherapy for Patients With Locally Advanced Unresectable Stage III Non-small-cell Lung Cancer.
    Tanaka H; Hasegawa Y; Makiguchi T; Okumura F; Tabe C; Shiratori T; Ishioka Y; Itoga M; Taima K; Yokouchi J; Hatayama Y; Aoki M; Tasaka S
    Clin Lung Cancer; 2021 Jan; 22(1):42-48. PubMed ID: 33158764
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A retrospective analysis of safety and efficacy of weekly nab-paclitaxel as second-line chemotherapy in elderly patients with advanced squamous non-small-cell lung carcinoma.
    Jin F; Zhu H; Shi F; Kong L; Yu J
    Clin Interv Aging; 2016; 11():167-73. PubMed ID: 26929611
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of recurrent and platinum-refractory stage IV non-small cell lung cancer with nanoparticle albumin-bound paclitaxel (nab-paclitaxel) as a single agent.
    Saxena A; Schneider BJ; Christos PJ; Audibert LF; Cagney JM; Scheff RJ
    Med Oncol; 2016 Feb; 33(2):13. PubMed ID: 26749586
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy analysis by histology of weekly nab-paclitaxel in combination with carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer.
    Socinski MA; Okamoto I; Hon JK; Hirsh V; Dakhil SR; Page RD; Orsini J; Yamamoto N; Zhang H; Renschler MF
    Ann Oncol; 2013 Sep; 24(9):2390-6. PubMed ID: 23842283
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A dose finding study of weekly and every-3-week nab-Paclitaxel followed by carboplatin as first-line therapy in patients with advanced non-small cell lung cancer.
    Socinski MA; Manikhas GM; Stroyakovsky DL; Makhson AN; Cheporov SV; Orlov SV; Yablonsky PK; Bhar P; Iglesias J
    J Thorac Oncol; 2010 Jun; 5(6):852-61. PubMed ID: 20521351
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Randomized Phase III Study Comparing Carboplatin With Nab-Paclitaxel Versus Docetaxel for Elderly Patients With Squamous-Cell Lung Cancer: Study Protocol.
    Kogure Y; Saka H; Takiguchi Y; Atagi S; Kurata T; Ebi N; Inoue A; Kubota K; Takenoyama M; Seto T; Kada A; Yamanaka T; Ando M; Yamamoto N; Gemma A; Ichinose Y
    Clin Lung Cancer; 2018 Sep; 19(5):e711-e715. PubMed ID: 29861395
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II trial of nanoparticle albumin-bound paclitaxel, carboplatin, and bevacizumab in first-line patients with advanced nonsquamous non-small cell lung cancer.
    Reynolds C; Barrera D; Jotte R; Spira AI; Weissman C; Boehm KA; Pritchard S; Asmar L
    J Thorac Oncol; 2009 Dec; 4(12):1537-43. PubMed ID: 19887966
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of weekly nab-paclitaxel plus carboplatin in patients with advanced non-small cell lung cancer.
    Satouchi M; Okamoto I; Sakai H; Yamamoto N; Ichinose Y; Ohmatsu H; Nogami N; Takeda K; Mitsudomi T; Kasahara K; Negoro S
    Lung Cancer; 2013 Jul; 81(1):97-101. PubMed ID: 23545279
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.